NICE Rejects Novartis’ Afinitor, Citing Irrelevant Evidence And High Cost
This article was originally published in The Pink Sheet Daily
NICE has rejected Novartis’ Afinitor for breast cancer, citing excessive cost and shooting down three out of four evidence submissions.
You may also be interested in...
Novartis’ discount for Afinitor in breast cancer has failed to convince NICE that the drug is cost-effective.
Novartis intends to improve productivity and absorb pricing pressures by closing two Swiss manufacturing facilities and transferring some research to the U.S.
The United Kingdom is creating a £600 million Cancer Drugs Fund to improve treatment access but a consultation document on the initiative is doing little to ease concerns about regional disparities in care.